Loading...
*  HIV vaccine
This results in an impediment to the development of a T cell response against the inserted antigen (HIV antigens) Additionally ... Federal Domestic HIV/AIDS Resource HIVtest.org - Find an HIV testing site near you Potential HIV vaccine using adenoviridae ... This HIV vaccine uses a "dead" version of HIV-1 for the first time. The outcome of the phase 1 human clinical trial has turned ... HIV Vaccine Trials Network World AIDS Vaccine Day Sharp, Paul M.; Hahn, Beatrice H. (2011-09-01). "Origins of HIV and the AIDS ...
*  José Esparza
Contributing to the development of ethical guidelines of conduct for HIV-vaccine trials. Leadership to ensure that future HIV ... Drake, S; Schaffer, PA; Esparza, J; Mayor, HD (Jul 1974). "Complementation of adeno-associated satellite viral antigens and ... He then joined the Bill and Melinda Gates Foundation(Seattle) from 2004 to 2014, first as senior adviser on HIV Vaccines, and ... He is known for his efforts to promote the international development and testing of vaccines against HIV/AIDS. During 17 years ...
*  HIV and pregnancy
Another screening test that is more specific is the HIV antigen/antibody test. This is a newer blood test that can detect HIV ... A qualitative HIV DNA PCR assay is recommended as it will detect pro-viral HIV DNA since HIV RNA may be suppressed by ART. In ... HIV testing begins with a screening test. The most common screening test is the rapid HIV antibody test which tests for HIV ... Performance of the Alere Determine HIV-1/2 Ag/Ab Combo Rapid Test with specimens from HIV-1 seroconverters from the US and HIV- ...
*  Gene therapy
All five patients had stable or increased immune response to HIV antigens and other pathogens. This was the first evaluation of ... a gene-based immunotherapy for the treatment of HIV that uses a lentiviral vector to deliver an antisense gene against the HIV ... In a phase I clinical trial, five subjects with chronic HIV infection who had failed to respond to at least two antiretroviral ... "Penn Medicine presents HIV gene therapy trial data at CROI 2009". EurekAlert!. 10 February 2009. Retrieved 19 November 2009. " ...
*  Diagnosis of HIV/AIDS
If antibodies to HIV are present in the serum, they may bind to these HIV antigens. The plate is then washed to remove all ... such as HIV-I GAG, HIV-II GAG, HIV-env, or the HIV-pol. Since these tests are relatively expensive, the blood is screened by ... RIBA HIV-1/HIV-2 SIA) as a supplemental (confirmatory) test for HIV-1 and HIV-2 infections". Transfusion science. 18 (1): 63-69 ... In general diagnostics, p24 antigen tests are used for early detection of HIV, as p24 antigen rises soon after infection ...
*  ELISA
If antibodies to HIV are present in the serum, they may bind to these HIV antigens. The plate is then washed to remove all ... For the detection of HIV antibodies, the wells of microtiter plate are coated with the HIV antigen. Two specific antibodies are ... If antibodies are present, the antigen-antibody reaction occurs. No antigen is left for the enzyme-labelled specific HIV ... The labeled antigen competes for primary antibody binding sites with the sample antigen (unlabeled). The less antigen in the ...
*  Modified vaccinia Ankara
In macaques, DNA-based HIV vaccines can be effectively boosted with recombinant MVA-based vaccines expressing HIV antigens. ... Currently, the use of MVA as a recombinant HIV vaccine (MVA-B) is being tested in approximately 300 volunteers in several Phase ... the most common being a vaccine delivery system for antigens. Concerns about the safety of the vaccinia virus have been ... which indicate the progress of genetic recombination with the transgene of an antigen (green, colorless, red). MVA is widely ...
*  Viral load monitoring for HIV
... the FDA approved the first diagnostic test capable of detecting HIV antigens and HIV antibodies. The Abbott ARCHITECT HIV Ag/Ab ... An HIV antibody test usually detects the HIV antibodies within two to eight weeks, but can have a valid negative result for a ... Viral load monitoring is used by HIV-positive people to develop a plan for their personal treatment of HIV/AIDS. A count of the ... Viral load monitoring for HIV is the regular measurement of the viral load of individual HIV-positive people as part of their ...
*  Endogenous retrovirus
The potential advantage of this novel approach is that, by using HERV antigens as surrogate markers of HIV-infected cells, it ... The hypothesis that HIV induces HERV expression in HIV-infected cells led to the proposal that a vaccine targeting HERV ... could circumvent the difficulty inherent in directly targeting notoriously diverse and fast-mutating HIV antigens. There are a ... Immunological studies have shown some evidence for T cell immune responses against HERVs in HIV-infected individuals. ...
*  Western lowland gorilla
Out of 2,934 gorilla samples, 70 reacted with at least one HIV-1 antigen. These samples came from four field sites, all located ... The SIV or Simian immunodeficiency virus that infects them is similar to a certain strain of HIV-1. The HIV-1 virus exhibits ... Takebe, Y; Uenishi, R; Li, X (2008). "Global Molecular Epidemiology of HIV: Understanding the Genesis of AIDS Pandemic". HIV-1 ... HIV-1, is composed of four phylogenetic lineages, which at some point in time have independently gone through cross-species ...
*  Major histocompatibility complex, class II, DQ alpha 1
1991). "Interaction of CD4 with HLA class II antigens and HIV gp120". Immunogenetics. 34 (2): 121-8. doi:10.1007/BF00211424. ... Clayton LK, Sieh M, Pious DA, Reinherz EL (1989). "Identification of human CD4 residues affecting class II MHC versus HIV-1 ... Rosenstein Y, Burakoff SJ, Herrmann SH (1990). "HIV-gp120 can block CD4-class II MHC-mediated adhesion". J. Immunol. 144 (2): ... 1988). "Inhibition of CD4+ T cell function by the HIV envelope protein, gp120". J. Immunol. 141 (11): 3715-7. PMID 2846691. ...
*  HLA-DPB1
1991). "Interaction of CD4 with HLA class II antigens and HIV gp120". Immunogenetics. 34 (2): 121-8. doi:10.1007/BF00211424. ... HLA class II histocompatibility antigen, DP(W2) beta chain is a protein that in humans is encoded by the HLA-DPB1 gene. HLA-DPB ... 1991). "Modulation of the HLA class II antigen at a molecular level by maternal serum among cord blood cells and unrelated ... Eiermann TH, Uhl S, Fakler J, Goldmann SF (1992). "A novel HLA-DPB1 sequence, DPB1*2301". Tissue Antigens. 40 (2): 108-10. doi: ...
*  HLA-DOB
1994). "HLA class II antigens and the HIV envelope glycoprotein gp120 bind to the same face of CD4". J. Immunol. 152 (9): 4475- ... 1991). "Interaction of CD4 with HLA class II antigens and HIV gp120". Immunogenetics. 34 (2): 121-8. doi:10.1007/BF00211424. ... 1994). "HIV-1 gp41 binding proteins and antibodies to gp41 could inhibit enhancement of human Raji cell MHC class I and II ... 1993). "HIV-1 envelope protein is expressed on the surface of infected cells before its processing and presentation to class II ...
*  HLA-DR
1991). "Interaction of CD4 with HLA class II antigens and HIV gp120". Immunogenetics. 34 (2): 121-8. doi:10.1007/BF00211424. ... Identification of these antigens has led to greater success and longevity in organ transplant. Antigens most responsible for ... The complex of HLA-DR (Human Leukocyte Antigen - antigen D Related) and its ligand, a peptide of 9 amino acids in length or ... 2004). "HIV/SIV escape from immune surveillance: focus on Nef". Curr. HIV Res. 2 (2): 141-51. doi:10.2174/1570162043484924. ...
*  HLA-DQA2
1994). "HLA class II antigens and the HIV envelope glycoprotein gp120 bind to the same face of CD4". J. Immunol. 152 (9): 4475- ... 1991). "Interaction of CD4 with HLA class II antigens and HIV gp120". Immunogenetics. 34 (2): 121-8. doi:10.1007/BF00211424. ... 1994). "HIV-1 gp41 binding proteins and antibodies to gp41 could inhibit enhancement of human Raji cell MHC class I and II ... Also known as HLA-DXA or DAAP-381D23.2, it is part of the human leucocyte antigen system. The protein encoded by this gene is ...
*  HLA-DRB3 (gene)
1991). "Interaction of CD4 with HLA class II antigens and HIV gp120". Immunogenetics. 34 (2): 121-8. doi:10.1007/BF00211424. ... 1991). "The HIV core protein p24 inhibits interferon-gamma-induced increase of HLA-DR and cytochrome b heavy chain mRNA levels ... Gorski J, Mach B (1986). "Polymorphism of human Ia antigens: gene conversion between two DR beta loci results in a new HLA-D/DR ... HLA class II histocompatibility antigen, DRB3-1 beta chain is a protein that in humans is encoded by the HLA-DRB3 gene. The ...
*  HLA-DRB5
1991). "Interaction of CD4 with HLA class II antigens and HIV gp120". Immunogenetics. 34 (2): 121-8. doi:10.1007/BF00211424. ... 1991). "The HIV core protein p24 inhibits interferon-gamma-induced increase of HLA-DR and cytochrome b heavy chain mRNA levels ... HLA class II histocompatibility antigen, DRB5 beta chain is a protein that in humans is encoded by the HLA-DRB5 gene. The ... Clayton LK, Sieh M, Pious DA, Reinherz EL (1989). "Identification of human CD4 residues affecting class II MHC versus HIV-1 ...
*  HLA-DRA
1991). "Interaction of CD4 with HLA class II antigens and HIV gp120". Immunogenetics. 34 (2): 121-8. doi:10.1007/BF00211424. ... 2004). "HIV/SIV escape from immune surveillance: focus on Nef". Curr. HIV Res. 2 (2): 141-51. doi:10.2174/1570162043484924. ... Anderson JL, Hope TJ (2005). "HIV accessory proteins and surviving the host cell". Current HIV/AIDS reports. 1 (1): 47-53. doi: ... Stove V, Verhasselt B (2006). "Modelling thymic HIV-1 Nef effects". Curr. HIV Res. 4 (1): 57-64. doi:10.2174/157016206775197583 ...
*  HLA-DRB4
1991). "Interaction of CD4 with HLA class II antigens and HIV gp120". Immunogenetics. 34 (2): 121-8. doi:10.1007/BF00211424. ... 1991). "The HIV core protein p24 inhibits interferon-gamma-induced increase of HLA-DR and cytochrome b heavy chain mRNA levels ... Clayton LK, Sieh M, Pious DA, Reinherz EL (1989). "Identification of human CD4 residues affecting class II MHC versus HIV-1 ... Rosenstein Y, Burakoff SJ, Herrmann SH (1990). "HIV-gp120 can block CD4-class II MHC-mediated adhesion". J. Immunol. 144 (2): ...
*  HLA-DR3
Mann DL, Murray C, O'Donnell M, Blattner WA, Goedert JJ (1990). "HLA antigen frequencies in HIV-1-related Kaposi's sarcoma". J ... HLA-DR3 is composed of the HLA-DR17 and HLA-DR18 split 'antigens' serotypes. DR3 is a component gene-allele of the AH8.1 ... Pollack MS, Gold J, Metroka CE, Safai B, Dupont B (1984). "HLA-A,B,C and DR antigen frequencies in acquired immunodeficiency ... 2007). "Primary sclerosing cholangitis is associated with extended HLA-DR3 and HLA-DR6 haplotypes". Tissue Antigens. 69 (2): ...
*  GBA3
... type 1 monomeric gp120 as novel antigens for HIV vaccine design". J. Virol. 77 (10): 5889-901. doi:10.1128/JVI.77.10.5889- ... Wolk T, Schreiber M (2006). "N-Glycans in the gp120 V1/V2 domain of the HIV-1 strain NL4-3 are indispensable for viral ... Papandreou MJ, Fenouillet E (1997). "Effect of various glycosidase treatments on the resistance of the HIV-1 envelope to ... Pantophlet R, Wilson IA, Burton DR (2003). "Hyperglycosylated mutants of human immunodeficiency virus (HIV) ...
*  GBA2
Type 1 Monomeric gp120 as Novel Antigens for HIV Vaccine Design". J. Virol. 77 (10): 5889-901. doi:10.1128/JVI.77.10.5889- ... Wolk T, Schreiber M (2007). "N-Glycans in the gp120 V1/V2 domain of the HIV-1 strain NL4-3 are indispensable for viral ... Papandreou MJ, Fenouillet E (1997). "Effect of various glycosidase treatments on the resistance of the HIV-1 envelope to ... 1993). "Site-specific N-glycosylation and oligosaccharide structures of recombinant HIV-1 gp120 derived from a baculovirus ...
*  DNA vaccination
"Enhancement of cell-mediated immunity against HIV-1 induced by coinnoculation of plasmid-encoded HIV-1 antigen with plasmid ... Tobery, T.W.; Siliciano, R.F. (1997). "Targeting of HIV-1 Antigens for Rapid Intracellular Degradation Enhances Cytotoxic T ... The antigen-presenting cell then travels to the lymph nodes and presents the antigen peptide and costimulatory molecule ... This is true for intracellular and plasma membrane-bound antigens, but not for secreted antigens, which seem to generate TH2 ...
*  Immune network theory
The vaccine concept comprised complexes of an anti-anti-HIV antibody and an HIV antigen, and was designed to induce the ... For example, low or high doses of an antigen can cause the system to switch to a suppressed state for the antigen, while ... Following an infection with HIV that manages to establish itself, there is a complex interaction between the HIV virus, the T ... An immune network model for HIV pathogenesis was published in 1994 postulating that HIV-specific T cells are preferentially ...
*  HVTN 505
5 as a live vector vaccine which was carrying artificial genetic material matching HIV antigens of the three major HIV subtypes ... "Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, ... "Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, ... Melville, Nancy A. "HIV Vaccine Study Goal Shifts to HIV Prevention". Medscape. Retrieved 2 September 2011. NIAID Office of ...
*  Phage display
Instead, one could cleave in a section between the bead and the antigen to elute. Since the pIII is intact it does not matter ... "CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range". J. Mol. ... The technique is also used to determine tumour antigens (for use in diagnosis and therapeutic targeting) and in searching for ... novel expression vectors that display cloned antigens on the virion surface". Science. 228 (4705): 1315-7. Bibcode:1985Sci... ...
*  Needlestick injury
"The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens". Science. 280 (5371): 1884-8. Bibcode:1998Sci...280.1884W ... There is no vaccine for HIV. When the source of blood is known to be HIV positive, a 3-drug regimen is recommended by the CDC; ... "HIV Infection, Risk, Prevention, and Testing Behaviors among Persons Who Inject Drugs-National HIV Behavioral Surveillance: ... The overall risk of HIV infection after percutaneous exposure to HIV-infected material in the health care setting is 0.3%. ...